Baricitinib for the Management of SARS-CoV-2-Infected Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Baricitinib is known to reduce mortality and disease progression in COVID-19 patients; however, the data are inconsistent. Therefore, it needs to be explored to further understand the clinical benefits of this drug in the management of COVID-19 patients. Does baricitinib statistically significantly...
Saved in:
Main Authors: | Sivananthan Manoharan, Lee Ying Ying |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/2022/8332819 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Epstein Barr Virus Reactivation during COVID-19 Hospitalization Significantly Increased Mortality/Death in SARS-CoV-2(+)/EBV(+) than SARS-CoV-2(+)/EBV(−) Patients: A Comparative Meta-Analysis
by: Sivananthan Manoharan, et al.
Published: (2023-01-01) -
Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far
by: Radi Taha Alsafi
Published: (2022-01-01) -
Co-Occurrence of SARS-CoV-2 Infection and Inactivated SARS-CoV-2 Vaccination among Healthcare Workers
by: Cucunawangsih Cucunawangsih, et al.
Published: (2021-01-01) -
Computational analysis of SARS-CoV-2, SARS-CoV, and MERS-CoV genome using MEGA
by: Vipan Kumar Sohpal
Published: (2020-09-01) -
Clinical Traits of SARS-CoV-2 Infection
by: O. Yu. Zolnikova, et al.
Published: (2020-12-01)